

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
| Drug common name | NARAZACICLIB |
| INN | narazaciclib |
| Description | Narazaciclib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target cyclin-dependent kinase 4, NUAK family SNF1-like kinase 1, and cyclin-dependent kinase 6. |
| Classification | Small molecule |
| Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(c2ccc(Nc3ncc4cc(C#N)c(=O)n(C5CCCC5)c4n3)cc2)CC1 |
| PDB | — |
| CAS-ID | 1357470-29-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3115681 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | QJ8RO3296G (ChemIDplus, GSRS) |
